Stroke Care First week



Similar documents
Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

AHA/ASA Ischemic Stroke Performance Measures

ALBERTA PROVINCIAL STROKE STRATEGY (APSS)

Medical Management of Ischemic Stroke: An Update. Siddharth Sehgal, MD Medical Director, TMH Neuroscience Center

CLINICAL GUIDELINE FOR SECONDARY PREVENTION AFTER STROKE OR TIA (PRIMARY AND SECONDARY CARE CORNWALL) MANAGEMENT 1. Aim/Purpose of this Guideline

STROKE PREVENTION IN ATRIAL FIBRILLATION

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

Stroke Prevention and the In-House Model

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

National Sentinel Stroke Audit Phase I (organisational audit) 2006 Phase II (clinical audit) Report for England, Wales and Northern Ireland

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

New Anticoagulants and GI bleeding

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

Cilostazol versus Clopidogrel after Coronary Stenting

Assessment Blueprint for Stroke Medicine. Mini- DOPS MSF SESR CBD TP A R area

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

Anticoagulation Therapy Update

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

The International Agenda for Stroke

REMINDER: Please ensure all stroke and TIA patients admitted to hospital are designated as "Stroke Service" in Cerner.

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE

Atrial fibrillation. Quick reference guide. Issue date: June The management of atrial fibrillation

9/5/14. Objectives. Atrial Fibrillation (AF)

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

Acute Myocardial Infarction (the formulary thrombolytic for AMI at AAMC is TNK, please see the TNK monograph in this manual for information)

NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

Rx Updates New Guidelines, New Medications What You Need to Know

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

The author has no disclosures

2.5mg SC daily. INR target mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.

Birmingham, Sandwell and Solihull Cardiac and Stroke Network. Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement

Antiplatelet and Antithrombotics From clinical trials to guidelines

New Oral Anticoagulants. How safe are they outside the trials?

KIH Cardiac Rehabilitation Program

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness SOGH April

New in Atrial Fibrillation

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Health Professionals who Support People Living with Dementia

Service Specification Template Department of Health, updated June 2015

ACUTE STROKE PATHWAY

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

New Oral Anticoagulants

GP workshop. Maria Fitzpatrick Nurse Consultant Kings College Stroke Centre

DVT/PE Management with Rivaroxaban (Xarelto)

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

F A S T. Transient ischaemic attack (TIA)

S9 Administer thrombolytic treatment in acute ischaemic stroke

ACUTE STROKE REGISTRY (NJASR) VERSION 2.0) (Continued)

Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)

National Stroke Association s Guide to Choosing Stroke Rehabilitation Services

2016 International Stroke Conference Hot Topics Lori M. Massaro, MSN, CRNP Kari Moore, MSN, AGACNP-BC

Hospital-Based Sub-Acute Stroke Care and Secondary Prevention. Timothy Lukovits,, M.D.

Atherosclerosis of the aorta. Artur Evangelista

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Introduction. Background to this event. Raising awareness 09/11/2015

Appendix C Factors to consider when choosing between anticoagulant options and FAQs

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

STROKE SERIES SS10. Understanding thrombolysis treatment For stroke

Renovascular Hypertension

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Listen to your heart: Good Cardiovascular Health for Life

Cardiac Sources of Stroke. Robert N. Piana, M.D. Professor of Medicine Director, Adult Congenital Interventional Cardiology

Level III Stroke Center Data Collection Requirements

A PATIENT S GUIDE TO SECONDARY PREVENTION IN ACUTE CORONARY SYNDROME (ACS)

TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Evaluating ED Patients with Transient Ischemic Attack: Inpatient vs. Outpatient Strategies

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

WHY DO MY LEGS HURT? Veins, arteries, and other stuff.

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

NHS Midlands and East Stroke Services Specification

Protocol for the management of atrial fibrillation in primary care

NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION

Appendix L: HQO Year 1 Implementation Priorities

Understanding diabetes Do the recent trials help?

What is Vascular Surgery Worth to a Health Care System?

When a stroke happens

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

Transcription:

Stroke Care First week

Florence Nightingale (1820 1910)

Stroke Unit Dedicated personnel trained in stroke management Stepwise guidelines supported by explicit checklists Continuous monitoring available Stepwise guidelines for diagnosis and treatment Early care and rehabilitation by multidisciplinary team

Acute Stroke Unit: Functions (1) Management and monitoring (as described for ER) Confirmation of diagnosis and aetiology using stepwise approach Therapy as appropriate experimental treatments Prevention of early recurrence/progression of stroke Prevention of complications

Acute Stroke Unit: Functions (2) Reassurance and support for patient and family Assessment of risk factors for recurrence Immediate start of early rehabilitation Secondary prevention Routine follow-up at outpatient clinics Data bases for research

Acute Stroke Unit: Multidisciplinary Team Neurologist, on site neurosurgeon, on duty neuropsychiatrist, on call Internist/cardiologist Specialist nurses Physiotherapists Speech and occupational therapists Neuropsychologists Social workers Other consultants as required

First day post stroke NB list Clear airway Adequate oxygenation Swallowing ability Hydration Urinary incontinence Fever avoid/treat and investigate Prevent: DVT, pressure sores, aspiration and trauma

First day post stroke NB list Concomitant disease Review home medication Protection of a flaccid shoulder/positioning Information FROM patient and family TO PATIENT FAMILY

Acute Stroke Unit Functions And Facilities Management throughout the first three weeks...

Stroke morbidity

Stroke Units - Patterns of Death

Outcomes after stroke unit care

Stroke Treatment Year 2000 and Beyond Secondary prevention Full recovery Stroke onset Call emergency services Activated (15 minutes) Drugs administered stroke-treatment cocktail Brain scan Neuroprotective drug infused during transport ER stroke team

Florence Nightingale (1820 1910)

Secondary Prevention Antiplatelet agents Aspirin -Antiplatelet Trialists Collaboration -25% RR for Stroke -Dose 50-325mg Combination Aspirin and Extended Release Dipyridamole -Better than Aspirin (ESPS-2) -23% RR over Aspirin for stroke Clopidogrel (CAPRIE) -8% RR over Aspirin for stroke -Cost / Safer than Ticlopidine Ticlopidine (TASS) -21% RR over Aspirin for stroke -Side effects

New vs. Old

Anticoagulation Warfarin (Cardiogenic Embolism) Atrial Fibrillation Warfarin with INR 2.0 3.0 70% risk reduction Only reason NOT to use Warfarin is an absolute contraindication Aspirin if Warfarin cannot be used Acute MI or LV Thrombus Cardiomyopathy

Bloodpressure Straight line relationship between level of BP and stroke risk Post-Stroke Hypertension 7 RCT s 15527 pt s with stroke, TIA or ICH Followed for 2 5 years Clear risk reduction of recurrent stroke, MI and vascular events related to degree of BP lowering HOPE 24% stroke, MI and death PROGRESS 43% in recurrent stroke (Both HT and non HT pt s)

Bloodpressure AHA Guidelines 2006 All patients with stroke/tia need to be on anti hypertensive treatment Both hypertensive and non hypertensive stroke survivors should be treated ( 10 / 5 ; < 120/80) Lifestyle modifications

Carotid Endarterectomy Stroke/TIA with ipsilateral Carotid Stenosis 70% SURGERY advised MUST be done in 2 weeks If surgery cannot be done consider CAS

Cholesterol lowering Patients with stroke/tia with Elevated cholesterol Comorbid coronary artery disease Evidence of atherosclerosis Manage according to NCEP III guidelines includes statins; LDL-C < 2.6mmol/L

Diabetes Patients with stroke/tia Treat BP to <135/85 Usually combination therapy ACEI or ARB have shown clear decreased renal disease progression Glucose control prevents microvascular complications HbA1C 7%

Florence Nightingale (1820 1910)

Brain Attack The 4.5 Golden Hours

EUSI : Goal in Acute Management To improve stroke outcome through improved early management, emergency treatment and acute intervention

Thrombolysis Status 2007 Meta analysis of all thrombolytic Rx in 3h s Prim. Outcome CONTROL GP = 68.3% Prim. Outcome TREATMENT = 55.2% ARR = 13.1%p=.00002 THUS NNT = 7.7 SITS MOST 6483pt Rx by 31/8/06 Independence = 54.3% Mortality = 11.3% Symptomatic ICH = 1.7%

PRIMARY PREVENTION SECONDARY PREVENTION ORGANISATION OF STROKE SERVICES ACUTE CARE COMPREHENSIVE REHABILITATION

Florence Nightingale (1820 1910)

Emergency Medical Services Full partners in acute stroke care Recognition of stroke using simple criteria High priority code for stroke Urgent transport to best-equipped hospital

Multidisciplinary Team Prevent complications - through vigilant delivery of care Prevent avoidable disability - through early rehabilitation Prevent recurrence - through appropriate secondary prevention

Stroke Unit Essentials Educating Training Level 1 evidence Weekly program Formal education 1-6 days/year Themes: a)team pt s + carers + multidisc. b)early + intensive rehab c)staff with special stroke interest d)active carer involvement

Stroke Unit Staff This is true 24 / 7 / 365 service! Educate, educate, educate ENTHUSIASM and KNOWHOW INVEST IN PEOPLE

Our Motivation The patient like art, is bigger than we are. He will have the last word. He will outlast us. His pain will be ours, and his terror, and his hopes, and finally, perhaps, his illness. For what are we all, ultimately but patients John H. Stone M.D.

Florence Nightingale (1820 1910)